Aster & Links Achieves Leasing Milestone with One-Third of Residential Units Now Leased

Boeing (BA) received FAA certification for its 737 MAX 10, unlocking 1,555 orders. A supplier dispute halted 777 freighter production, costing $6.5M daily. Q2 saw 67% revenue growth to $24.6B but a $0.76 loss per share. Q3 results on October 27 will show if deliveries and ramp-up offset bottlenecks. Analysts' price target is $267.

Tovecimig (CTX-009) plus paclitaxel showed improved objective response rates (18.0% vs 5.3%) over paclitaxel alone in advanced biliary tract cancer, meeting the primary endpoint of the phase 2/3 COMPANION-002 trial. Median PFS was 4.7 months vs 2.6 months, but OS was similar (8.9 vs 9.4 months). The trial involved 168 patients and was presented at the 2026 ESMO Congress. According to Compass Therapeutics, the combination represents a promising new strategy for biliary tract cancer.

Teck Resources Limited reported a strike at its Highland Valley Copper mine in British Columbia, reducing operations. The impact on production depends on the strike's duration. The company has contingency plans and aims for a fair collective agreement. Teck warned of potential effects on previously issued guidance due to the labor disruption.

Teck Resources Limited reports a strike at its Highland Valley Copper mine, leading to reduced operations. Production impact remains uncertain, depending on the strike's duration, according to the company.

Moderna and Merck's melanoma vaccine trial showed a 42% reduction in tumor recurrence and 38% in distant spread, impressing doctors. However, shares of both companies fell as investors questioned the vaccine's broader potential and commercial success. Analysts raised concerns about costs and competition. The full data will be presented at a medical conference.

Amgen's Imdelltra, combined with AstraZeneca's Imfinzi, reduced lung cancer death risk by 58% in a trial. Amgen reports median survival of 21.1 months vs. 12.7 months with Imfinzi alone. Imdelltra sales grew to $288M in Q2 2026, but represents only 2.9% of Amgen's total revenue. Analysts expect Amgen's revenue to grow 4% annually through 2030.